What dose of injectable vitamin K (phytonadione) should be given to a pediatric patient with an elevated INR?

Vitamin K Dosing for Elevated INR in Pediatric Patients

For pediatric patients with elevated INR, administer intravenous vitamin K at a dose of 30 mcg/kg (0.03 mg/kg) for INR >8 without significant bleeding, or 1-2 mg for neonates/infants with hemorrhagic disease, with immediate fresh frozen plasma (FFP) or prothrombin complex concentrates if active bleeding is present. 1

Dosing Based on Clinical Scenario

For Warfarin-Induced Coagulopathy (No Active Bleeding)

• When INR is excessively prolonged (usually >8) without significant bleeding: Use IV vitamin K at 30 mcg/kg (0.03 mg/kg) 1
• This dose is extrapolated from limited pediatric data but represents the best available evidence for this population 1
• The subcutaneous route is preferred when IV administration can be avoided, though IV may be necessary in urgent situations 2

For Neonatal Hemorrhagic Disease

• Treatment dose: 1 mg subcutaneously or intramuscularly 2
• Higher doses may be necessary if the mother has been receiving oral anticoagulants 2
• Response should occur within 2-4 hours; failure to respond suggests an alternative diagnosis 2

For Active Bleeding with Elevated INR

• Immediate reversal is required: Use FFP, prothrombin complex concentrates, or recombinant factor VIIa in addition to vitamin K 1
• Do not delay blood product administration while waiting for vitamin K to take effect 1
• Vitamin K should still be given concurrently as it addresses the underlying deficiency 2

Administration Guidelines

Route Selection

• Subcutaneous route is preferred when immediate reversal is not required 2
• IV administration should be reserved for situations where rapid reversal is essential 2
• When IV administration is necessary, infuse very slowly, not exceeding 1 mg per minute to minimize risk of anaphylactoid reactions 2

Dilution and Preparation

• May be diluted with preservative-free 0.9% Sodium Chloride, 5% Dextrose, or 5% Dextrose and Sodium Chloride 2
• Benzyl alcohol-containing diluents must be avoided in neonates due to toxicity risk 2
• Administer immediately after dilution and discard unused portions 2
• Protect from light at all times during preparation and administration 2

Monitoring and Follow-Up

Expected Response Timeline

• Check INR at 6-8 hours after parenteral administration 2
• If INR has not shortened satisfactorily by 6-8 hours, repeat the dose 2
• Continue monitoring until INR is in therapeutic range (2.0-3.0 for most indications) 1

Target INR for Ongoing Anticoagulation

• Target INR of 2.5 (range 2.0-3.0) for most pediatric indications 1
• Exception: prosthetic cardiac valves require adherence to adult recommendations which may differ 1

Critical Pitfalls to Avoid

Dosing Errors

• Do not underdose in emergency situations: While 30 mcg/kg is appropriate for asymptomatic INR elevation, active bleeding may require higher doses (up to 1-2 mg in small children) based on clinical judgment 1, 2
• Avoid excessive dosing: Overcorrection can make re-anticoagulation difficult and may increase thrombotic risk 1

Administration Safety

• Never administer IV vitamin K rapidly: Anaphylactoid reactions, including hypotension and shock, can occur with rapid infusion 2
• Do not use benzyl alcohol-preserved diluents in neonates: This can cause fatal gasping syndrome 2

Clinical Management

• Do not rely on vitamin K alone for active bleeding: Blood products provide immediate factor replacement while vitamin K takes hours to work 1, 2
• Do not assume vitamin K deficiency without proper evaluation: Failure to respond to vitamin K suggests an alternative coagulation disorder requiring different management 2

Special Considerations for Pediatric Population

• Infants require higher weight-based warfarin doses (average 0.33 mg/kg) compared to teenagers (0.09 mg/kg) to maintain therapeutic INR, which may influence vitamin K dosing needs 1
• Point-of-care INR monitoring is accurate and reliable in children and reduces trauma from repeated venipunctures 1
• Patient and family education is crucial: Adequate education protocols significantly reduce bleeding events in children on warfarin therapy 1